Have Any Questions?


Your Current Position:Home >> Partnering >> Product License

MabSpace is seeking parnters for out-licensing of the ex-China rights of its lead therapeutic assets:

1) A second generation PD-L1 antibody with pH-dependent antigen binding and recylcing properties (starting FIH in 2017)

2) A best-in-class VEGFR2 neutralizing antibody at Pre-IND stage (FIH expected to start in 2018)

3) A best -in class OX40 agonist antibody in IND-enabling study

4) A best-in class CSF1R blocking antibody in IND-enabling study

Copyright © 2017 Mabspace Biosciences All rights reserved